Developmental Research Program

发展研究方案：摘要/摘要 发展研究计划(DRP)的目的是资助高度创新的翻译研究 结直肠癌(CRC)或胰腺癌(PDAC)目前缺乏 孢子指南，但这可能成为完整的孢子项目与必要的DRP支持，或竞争 成功地获得了孢子机制以外的资金。DRP提供了一个独特的场所 提供关键的财政支持，以及针对疾病的智力和资源专门知识，通过 对新想法或倡议做出快速响应的计划，包括来自其当前工作的调查人员 不能只专注于CRC或PDAC研究。该计划植根于所拥护的合作精神 由GI孢子领导层，它有从其他学科带来调查人员的广泛记录 进入CRC和/或PDAC研究领域。DRP的力量在于它有能力提供资金 获得整个GI孢子内的所有关键专业知识和资源所需的支持，包括 建议的核心。这将使我们能够开发创新的、由调查人员发起的项目，这些项目有可能 沿着基础和/或人口的道路，蓬勃发展为可靠且富有成效的翻译研究项目 研究项目侧重于人类临床标本/患者群体的研究。DRP将由孢子的主要调查人员进行调查，包括谢赫科学主任阿尼尔班·迈特拉博士 艾哈迈德胰腺癌研究中心，病理和医学系教授 UT MD Anderson癌症中心(UTMDACC)和Scott Kopetz博士的翻译分子病理学， 消化内科副教授兼翻译研究副主任委员 肿瘤学。DRP不仅将包括UTMDACC，还将包括我们的合作伙伴机构Johns 霍普金斯大学(JHU)和德克萨斯医学中心内的其他卓越中心，提供 为促进PDAC和CRC的创新翻译研究项目提供了前所未有的苗床。本计划将以一页意向书(LOI)的形式征求预先建议书，并在由 民研计划领导层将邀请申请人提交一份完整的建议书供审查。 DRP主任将帮助调查人员提交建议，以制定翻译研究目标和计划 与GI孢子的整体主题相关，因为许多申请者可能没有这种类型的专业知识 研究。首要目标将是促进研究活动，使之能够提出可行的人类 已资助建议书的未来迭代的终点。因此，这一过程将是一项重要的教育活动。 预计这将进一步刺激CRC或PDAC的翻译研究，并鼓励 翻译研究中的基础科学研究人员和临床研究人员。

DEVELOPMENTAL RESEARCH PROGRAM: Summary/Abstract The purpose of the Developmental Research Program (DRP) is to fund highly innovative translational studies in colorectal cancer (CRC) or pancreatic cancer (PDAC) that currently lack a human endpoint as mandated by the SPORE guidelines, but that could become full SPORE projects with requisite DRP support, or compete successfully for funding outside of the SPORE mechanism. The DRP provides a unique venue for making available critical financial support, as well as disease-specific intellectual and resource expertise, through a program that is rapidly responsive to new ideas or initiatives, including from investigators whose current work may not focus exclusively in CRC or PDAC research. This program is rooted in a spirit of collaboration espoused by the GI SPORE leadership, which has an extensive track record of bringing investigators from other disciplines into the field of CRC and/or PDAC research. The strength of the DRP rests in its ability to make available financial support needed to access all the critical expertise and resources within the entire GI SPORE, including the proposed Cores. This will allow us to develop innovative, investigator-initiated projects that have the potential to flourish into reliable and productive translational research projects along a path from basic and/or population research projects into research focused on human clinical specimens/patient populations. The DRP will be coled by principal investigators of the SPORE including Dr. Anirban Maitra, the Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research, and Professor in the Departments of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center (UTMDACC) and Dr. Scott Kopetz, Associate Professor and Deputy Chair for Translational Research in the Department of Gastrointestinal Medical Oncology. The DRP will incorporate not only UTMDACC, but also our collaborating partner institution Johns Hopkins University (JHU) and other centers of excellence within the Texas Medical Center, providing an unprecedented seedbed for promoting innovative translational research projects in PDAC and CRC. Preproposals in the form of one page letters of intent (LOI) will be solicited by the Program, and following review by the DRP leadership, applicants of the responsive pre-proposals will be invited to submit a full proposal for review. The DRP Directors will help investigators submitting proposals to formulate translational research aims and plans relevant to the overall themes of the GI SPORE, as many applicants may not have prior expertise in this type of research. The overarching goal will be to facilitate research activities that will enable proposing a feasible human endpoint for future iterations of the funded proposal. This process will therefore be a major educational activity that is further anticipated to stimulate translational research in CRC or PDAC and encourage the participation of both basic science researchers and clinical investigators in translational research.